The Globe and Mail reports in its Thursday edition that Echelon Partners analyst Andrew Semple thinks it is "an opportune time" to invest in Decibel Cannabis Company, expecting "strong" cash-flow generation in 2024 will "substantially derisk the company and support a valuation rerating." The Globe's David Leeder writes that Mr. Semple, also predicting an upcoming Health Canada review of the Cannabis Act should be "a positive industry catalyst," he started coverage of the Calgary-based company with a "speculative buy" recommendation. Mr. Semple says in a note: "Decibel is a standout among the publicly traded Canadian licensed producers for its multi-year track record of consistent profitable growth in an industry that has seen many LPs struggle to remain profitable and innovative. The company recently reported its 13th consecutive quarter of positive adjusted EBITDA and sixth consecutive quarter of positive adjusted net income." He set a share target of 35 cents which implies upside of 169 per cent from the stock's Tuesday closing price. The average target on the Street is 50 cents. Mr. Semple says, "Decibel's successful strategy has catapulted the business to the No. 2 LP spot in Canada by market share."